Joseph S. Zakrzewski, a director at AN2 Therapeutics, Inc. (NASDAQ:ANTX), recently purchased 2,000 shares of the company's common stock. The shares were acquired at a price of $1.40 each, totaling $2,800. Following this transaction, Zakrzewski now directly owns 125,199 shares.
Additionally, Zakrzewski holds an indirect interest in 405,880 shares through the Z3 Trust, where he serves as a trustee. This information was disclosed in a recent SEC filing, underscoring Zakrzewski's continued investment in AN2 Therapeutics.
In other recent news, AN2 Therapeutics has been the subject of several significant developments. The company's drug candidate EBO, developed to treat refractory nontuberculous mycobacterial infections, has seen mixed results in Phase 2 trials, influencing TD Cowen to adjust its rating from a Buy to a Hold status. The decision to proceed with the Phase 3 trial of EBO is expected to be made after discussions with the FDA in the first half of 2025.
AN2 Therapeutics has also received an extension for its research grant from the Bill & Melinda Gates Foundation, supporting its efforts in developing novel treatments for tuberculosis and malaria. This funding will aid in the discovery of inhibitors targeting aminoacyl-tRNA synthetases using AN2's proprietary boron chemistry platform.
Additionally, the company has implemented a stockholder rights plan following a significant acquisition of its shares by BML Investment Partners, designed to protect shareholders from potential coercive takeover tactics. Despite discontinuing its EBO-301 study due to insufficient improvement in sputum culture conversion, AN2 Therapeutics remains committed to its pipeline programs and has initiated Phase 1 and Phase 2 trials for Chagas disease and melioidosis respectively.
Evercore ISI maintains its 'In Line' rating for AN2 Therapeutics, noting the company's end-of-quarter cash reserves of $118 million as sufficient for reaching the crucial data readout phase.
InvestingPro Insights
Joseph S. Zakrzewski's recent purchase of AN2 Therapeutics shares comes at a time when the company's stock is trading at a significant discount to its 52-week high. According to InvestingPro data, AN2 Therapeutics' stock price is currently at just 6.08% of its 52-week high, suggesting a potential opportunity for value investors.
Despite the company's challenging financial performance, with a negative P/E ratio of -0.7 and an operating loss of $64.76 million over the last twelve months as of Q3 2023, there are signs of market optimism. The stock has shown impressive short-term gains, with a 29.91% price return over the past month and an 18.8% return over the last three months.
InvestingPro Tips highlight that AN2 Therapeutics is trading below its fair value, with analyst targets suggesting a fair value of $2 per share. This aligns closely with the InvestingPro Fair Value estimate of $2.01, indicating potential upside from the current price levels.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for AN2 Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.